Healthcare Providers and Services
Company Overview of Quest Diagnostics Inc.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV...
3 Giralda Farms
Madison, NJ 07940
Founded in 1967
Key Executives for Quest Diagnostics Inc.
Chief Executive Officer, President, Director and Member of Executive Committee
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice President
Total Annual Compensation: $550.0K
Senior Vice President of Operations
Total Annual Compensation: $536.5K
Chief Medical Officer, Senior Vice President and Group Executive of Diagnostic Solutions Businesses
Total Annual Compensation: $573.9K
Senior Vice President and Group Executive of Clinical Franchise Solutions
Total Annual Compensation: $534.6K
Compensation as of Fiscal Year 2014.
Quest Diagnostics Inc. Key Developments
Quest Diagnostics Declares Quarterly Dividend Payable on July 22, 2015
May 15 15
Quest Diagnostics announced it will pay a quarterly dividend on its common stock of $0.38 per share on July 22, 2015 to shareholders of record on July 8, 2015.
Quest Diagnostics Launches QNatal Advanced
May 12 15
Quest Diagnostics launched QNatal Advanced, a noninvasive prenatal screening service for detecting chromosomal abnormalities in high-risk pregnancies. QNatal Advanced analyzes cell-free fetal DNA in circulating maternal bloodÂ to screen for common and rare chromosomal abnormalities, including those associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome), as well as fetal sex aneuploidies and select copy number variants. The screening test analyzes more chromosomal regions than most other noninvasive prenatal tests, and can be used as early as 10 weeks into gestation. With results of a QNatal Advanced screen, a woman and her physician may be better positioned to assess the appropriateness of invasive diagnostic testing, such as amniocentesis, which carries a slight risk of miscarriage, to confirm a finding.
Quest Diagnostics Announces LeukoVantage, Advancing Precision Medicine for Hematologic Malignancies
May 4 15
Quest Diagnostics announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs). For MDS, LeukoVantage may detect certain molecular markers to help identify early stages of the disease, complementing conventional diagnostic techniques. MDS is typically diagnosed through a series of tests that include complete blood count (CBC), morphology, and cytogenetic (chromosomal) analysis. For MPN, LeukoVantage
may identify molecular markers that can aid the selection of certain targeted therapies, such as JAK2 inhibitors, and establishing a prognosis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|